

The listing Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-14 (Cancelled)

Claim 15 (Currently Amended) The method of Claim 26 ~~pharmaceutical composition of Claim 14~~, wherein the core particles comprise the active agent of topiramate and at least one excipient.

Claim 16 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 15, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres.

Claim 17 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 16, wherein the taste mask coating comprises between about 9% by weight and about 13% by weight of the pharmaceutical composition.

Claim 18 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 17, wherein the taste mask coating comprises about 11% by weight of the pharmaceutical composition.

Claim 19 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 18, wherein the core particles have an initial particle size between about 0.5 mm and 1.5 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.5 mm and 1.5 mm.

Claim 20 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 19, wherein the core particles have an initial particle size between about 0.710 mm and 1.18 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.850 mm and 1.18 mm.

Claim 21 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 20, wherein the binder is selected from povidone, HPMC, sodium alginate, panwar gum, acacia gum, gelatin, sugar, molasses, starch, pregelatinized starch, methycellulose, ethylcellulose or carboxymethylcellulose; and the taste mask coating comprises a taste masking agent and a disintegrant, wherein the taste masking agent is selected from cellulose acetate, methycellulose, ethylcellulose, a Eudragit or cellulose acetate butyrate; and the disintegrant is selected from povidone, cellulose, carboxymethylcellulose, croscarmellose sodium, magnesium aluminate silicate, starch, sodium starch glycolate, pregelatinized starch, alginic acid or guar gum.

Claim 22 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 21, wherein the binder is povidone, the taste masking agent is cellulose acetate and the disintegrant is povidone.

Claim 23 (Currently Amended) The ~~pharmaceutical composition~~ method of Claim 22, wherein the coated particles of the pharmaceutical composition are encapsulated.

Claim 24 (Cancelled)

Claim 25 (Cancelled)

Claim 26 (Currently Amended) A method of treating convulsions in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of the a pharmaceutical composition of Claims 14 comprising

(a) core particles containing an active agent of topiramate, wherein the core particles have an initial particle size between about 0.100 mm and 2.5 mm; and

(b) a taste mask coating, wherein the taste mask coating comprises between about 7% by weight and about 15% by weight of the pharmaceutical composition and wherein the coated particles of the pharmaceutical composition have a final particle size of about 0.100 mm to about 2.5 mm.

Claim 27 (Currently Amended) A method of treating epilepsy in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of the a pharmaceutical composition of Claims 14 comprising

(a) core particles containing an active agent of topiramate, wherein the core particles have an initial particle size between about 0.100 mm and 2.5 mm; and

(b) a taste mask coating, wherein the taste mask coating comprises between about 7% by weight and about 15% by weight of the pharmaceutical composition and wherein the coated particles of the pharmaceutical composition have a final particle size of about 0.100 mm to about 2.5 mm.

Claim 28 (New) The method of Claim 27, wherein the core particles comprise the active agent of topiramate and at least one excipient.

Claim 29 (New) The method of Claim 28, wherein the core particles comprise the active agent of topiramate, a binder and a diluent wherein the diluent is sugar spheres.

Claim 30 (New) The method of Claim 29, wherein the taste mask coating comprises between about 9% by weight and about 13% by weight of the pharmaceutical composition.

Claim 31 (New) The method of Claim 30, wherein the taste mask coating comprises about 11% by weight of the pharmaceutical composition.

Claim 32 (New) The method of Claim 31, wherein the core particles have an initial particle size between about 0.5 mm and 1.5 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.5 mm and 1.5 mm.

Claim 33 (New) The method of Claim 32, wherein the core particles have an initial particle size between about 0.710 mm and 1.18 mm and the coated particles of the pharmaceutical composition have a final particle size between about 0.850 mm and 1.18 mm.

Claim 34 (New) The method of Claim 33, wherein the binder is selected from povidone, HPMC, sodium alginate, panwar gum, acacia gum, gelatin, sugar, molasses, starch, pregelatinized starch, methycellulose, ethylcellulose or carboxymethylcellulose; and the taste mask coating comprises a taste masking agent and a disintegrant, wherein the taste masking agent is selected from cellulose acetate, methylcellulose, ethylcellulose, a Eudragit or cellulose acetate butyrate; and the disintegrant is selected from povidone, cellulose, carboxymethylcellulose, croscarmellose sodium, magnesium aluminate silicate, starch, sodium starch glycolate, pregelatinized starch, alginic acid or guar gum.

Claim 35 (New) The method of Claim 34, wherein the binder is povidone, the taste masking agent is cellulose acetate and the disintegrant is povidone.

Claim 36 (New) The method of Claim 35, wherein the coated particles of the pharmaceutical composition are encapsulated.